You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Drug Use Investigation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BENLYSTA® Special Drug Use Investigation

Recruiting
  • Systemic Lupus Erythematosus
  • Hiroshima, Japan
    GSK Investigational Site
Nov 24, 2022

Prostatic Tumors, Castration-Resistant Trial in Multiple Locations (Radium-223 dichloride (Xofigo, BAY 88-8223))

Active, not recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • Radium-223 dichloride (Xofigo, BAY 88-8223)
  • Multiple Locations, Japan
    (unnamed)
Feb 2, 2023

Xarelto for Venous Thromboembolism (VTE)

Completed
  • Venous Thromboembolism
  • Rivaroxaban (Xarelto, BAY59-7939)
  • Multiple Locations, Japan
    Many locations
Oct 30, 2022

(DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or

Completed
  • Endometriosis and Dysmenorrhea
  • Multiple Locations, Japan
    Many locations
Nov 13, 2022

Drug Use Investigation of COMIRNATY Intramuscular Injection

Active, not recruiting
  • COVID-19
  • BNT162b2
  • Tokyo, Japan
    PfizerLocal Country Office
Jan 9, 2023

Follistim Injection (Study P06132)(COMPLETED)

Completed
  • Anovulation
  • Follitropin beta
  • (no location specified)
Feb 2, 2022

1 of Follistim Injection (Study P06130)(COMPLETED)

Completed
  • Fertilization in Vitro
  • Follitropin beta
  • (no location specified)
Feb 2, 2022

Nasonex® Nasal Suspension 50 µg Long-term Designated Drug Use

Completed
  • Allergic Rhinitis
  • mometasone furoate
  • (no location specified)
Feb 7, 2022

Long Term Special Drug Use Investigation of Mepolizumab

Active, not recruiting
  • Asthma
  • NUCALA Injection
  • (no location specified)
Oct 27, 2021

Prospective, Non-interventional, Multi-center Post-authorization

Recruiting
  • Hypertension, Pulmonary
  • Riociguat (ADEMPAS, BAY63-2521)
  • Multiple Locations, Japan
    (unnamed)
Jan 10, 2023

Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Completed
  • Macular Degeneration
  • Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
  • Multiple Locations, Japan
    (unnamed)
Jan 9, 2023

BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

Recruiting
  • Dysphonia
  • Tokyo, Japan
    GSK Investigational Site
Oct 6, 2021

NTRK Gene Fusion - Positive Advanced or Recurrent Solid

Recruiting
  • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • Multiple Locations, Japan
    Many locations
Jan 20, 2023

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

Eylea in Babies Born Too Early Who HaveCondition of Eye Where

Not yet recruiting
  • Retinopathy of Prematurity
  • +2 more
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, Japan
    Many locations
Jan 20, 2023

Teduglutide in Japanese People With Short Bowel Syndrome

Recruiting
  • Short Bowel Syndrome
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Prospective, Non-interventional, Multi-center,

Recruiting
  • Hypertension, Pulmonary
  • Riociguat (ADEMPAS, BAY63-2521)
  • Multiple Locations, Japan
    Many Locations
Aug 17, 2022

Aflibercept Injection in Japanese Neovascular Glaucoma (NVG)

Recruiting
  • Neovascular Glaucoma
  • Aflibercept (Eylea, BAY86-5321)
  • Multiple Locations, Japan
    Many locations
Aug 17, 2022

Drug Use Investigation for Toviaz

Completed
Has Results
  • Overactive Bladder (OAB)
  • Fesoterodine (Toviaz)
  • (no location specified)
May 14, 2021

Ondexxya for Intravenous Injection 200mg Drug Use Result

Recruiting
  • Life Threatening Bleeding
  • Factor Xa Inhibitor
    • Tokyo, Japan
      Research Site
    Jul 7, 2022

    Prospective, Non-interventional, Post-authorization Safety Study

    Active, not recruiting
    • Thyroid Carcinoma
    • Sorafenib (Nexavar, BAY43-9006)
    • Multiple Locations, Japan
      (unnamed)
    Aug 18, 2022

    A 52-week Post-marketing, Observational Study to Confirm Safety

    Completed
    • Hypercholesterolemia
    • +2 more
    • Ezetimibe
    • Ezetimibe + other lipid-lowering medication(s)
    • (no location specified)
    Feb 7, 2022

    A 12-week Post-marketing, Observational Study to Confirm Safety

    Completed
    • Hypercholesterolemia
    • +2 more
    • Ezetimibe
    • Ezetimibe + other lipid-lowering medication(s)
    • (no location specified)
    Feb 7, 2022

    Confirm the Safety and Efficacy of MARVELON (Study P06083)

    Completed
    • Contraception
    • Ethinylestradiol + Desogestrel
    • (no location specified)
    Feb 2, 2022

    Regorafenib Post-marketing Surveillance in Japan

    Completed
    • Gastrointestinal Stromal Tumors
    • Regorafenib (Stivarga, BAY73-4506)
    • Multiple Locations, Japan
      (unnamed)
    Mar 21, 2022